Passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders

Agios (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. In 2017, Agios received approval from the FDA for IDHIFA® (enasidenib) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation, representing the first and only FDA-approved therapy for patients with R/R AML and an IDH2 mutation. IDHIFA was developed in collaboration with Celgene Corporation.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

March 5, 2018
Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018

February 15, 2018
FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

February 14, 2018
Agios Reports Fourth Quarter and Full Year 2017 Financial Results

Read More News

Associated Team Members

Craig Muir
Partner/Chief Technology Officer

Cary Pfeffer, M.D.

Kevin Starr